After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
Investors shouldn't give up on Gilead's Hep. C drug, Cramer says.
Gilead (GILD) stock was down in pre-market trading on Tuesday after Leerink cut its rating on shares to 'market perform.'
Here are Tuesday's top research calls, including upgrades for AutoZone and Eli Lilly, and downgrades for J.M. Smucker and Toll Brothers.
Stocks end Monday's session sharply lower as Wall Street grows restless ahead of the first presidential debate.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.